<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595021</url>
  </required_header>
  <id_info>
    <org_study_id>zsfud-obgyn-004</org_study_id>
    <nct_id>NCT02595021</nct_id>
  </id_info>
  <brief_title>Total/Subtotal Colectomy in Ovarian Cancer</brief_title>
  <official_title>A Phase II Study of Total or Subtotal Colectomy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Gynecologic Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and one year disease-free survival of
      total or subtotal colectomy and proctocolectomy in stage IIIc and stage IV epithelial
      ovarian, fallopian tube, and primary peritoneal cancer (EOC, FTC, PPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is to assess the perioperative complications, hospitalization expenses and days,
      and one year disease-free survival of patients who underwent total or subtotal colectomy as
      part of the surgical procedures for ovarian cancer, versus partial intestinal resection in
      the therapy for ovarian cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Assessed by Common Terminology Criteria for Adverse Events version 4.0 up to 30 days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of 12- month- disease non-progression</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients without progression in 12 months (From date of first chemotherapy until the date of first documented progression, assessed up to 12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initiation of the first cycle chemotherapy</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>To compare the date between surgery and initiation of the first cycle chemo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization expenses</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>the cost during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization days</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Secondary Malignant Neoplasm of Large Intestine</condition>
  <arm_group>
    <arm_group_label>Total or Subtotal Colectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Bowel Resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total or Subtotal Colectomy</intervention_name>
    <description>Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease &lt;=0.5cm)</description>
    <arm_group_label>Total or Subtotal Colectomy</arm_group_label>
    <other_name>Radical surgery</other_name>
    <other_name>Total Colectomy</other_name>
    <other_name>Subtotal Colectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Other Bowel Resection</intervention_name>
    <description>Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease &lt;=0.5cm)</description>
    <arm_group_label>Other Bowel Resection</arm_group_label>
    <other_name>Partial Colectomy</other_name>
    <other_name>Small bowel resection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years and ≤ 75 years.

          -  Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma with
             pathology confirmed International Federation of Gynecology and Obstetrics (FIGO) stage
             IIIc or IV

          -  Extensive colonic metastasis, tumor involving the major part of bowel surface and/or
             mesentery

          -  Optimal cytoreductive surgery, including hysterectomy, bilateral
             salpinges-oophorectomy, omentectomy, and resection of all metastatic lesions, with a
             residual disease no more than 0.5cm

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          -  American Society of Anesthesiologists (ASA) performance 1-2.

          -  Follow-up available.

          -  Written informed consent.

        Exclusion Criteria:

          -  Low-malignant potential ovarian tumor.

          -  Patient who underwent enterostomy in the surgery procedure.

          -  Tumor involving small intestine alone.

          -  More than 2 anastomoses.

          -  Other condition that could interfere with provision of informed consent, compliance to
             study procedures, or follow-up.

          -  Prior invasive malignancies within the last 5 years showing activity of disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rongyu Zang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuozhen Sun, MD</last_name>
    <phone>+862164041990</phone>
    <email>zhuozhen_sun@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuting Luan, RN</last_name>
    <phone>+862164041990</phone>
    <email>yutingluan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuozhen Sun, MD</last_name>
      <phone>+862164041990</phone>
      <email>zhuozhen_sun@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuting Luan, RN</last_name>
      <phone>+862164041990</phone>
      <email>yutingluan@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rongyu Zang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ShanghaiGOG.org</url>
    <description>Shanghai Gynecologic Oncology Group</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2015</study_first_posted>
  <last_update_submitted>July 23, 2016</last_update_submitted>
  <last_update_submitted_qc>July 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total or subtotal colectomy</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Complications</keyword>
  <keyword>One-year disease-free survival</keyword>
  <keyword>Stage IIIc</keyword>
  <keyword>Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

